NCT03284268 (RTB) is a NA clinical trial of VCN-01 in Retinoblastoma, Recurrent, sponsored by Fundació Sant Joan de Déu.

Who is sponsoring NCT03284268?

NCT03284268 is sponsored by Fundació Sant Joan de Déu.

What drugs are being tested in NCT03284268?

Interventions in NCT03284268: VCN-01.

What condition does NCT03284268 study?

NCT03284268 studies Retinoblastoma, Recurrent.

Is NCT03284268 still recruiting?

NCT03284268 is currently completed. Last updated 27 August 2024.

Last reviewed 2024-08-27 · How we verify

NCT03284268: RTB

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Evaluate Safety and the Oncolitic Adenovirus VCN-01 Activity in Patients With Refractory Retinoblastoma

Completed NA Last updated 27 August 2024

What this trial tests

NA trial testing VCN-01 in Retinoblastoma, Recurrent in 13 participants. Completed in 14 June 2024.

Timeline

6 September 2017

Primary endpoint
14 June 2024

14 June 2024

Quick facts

Lead sponsor	Fundació Sant Joan de Déu
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	13
Start date	6 September 2017
Primary completion	14 June 2024
Estimated completion	14 June 2024
Sites	1 location across Spain

Drugs / interventions tested

VCN-01 — full drug profile →

Conditions studied

Retinoblastoma, Recurrent — all drugs for Retinoblastoma, Recurrent →

Sponsor

Fundació Sant Joan de Déu — full company profile →

Who can join

Adults 1 to 12, any sex, with Retinoblastoma, Recurrent. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Phase I study, single site, open label with dose escalation, for evaluate safety and the oncolitic Adenovirus VCN-01 activity in patients with refractory retinoblastoma.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Viral vector platforms within the gene therapy landscape.
Bulcha JT, Wang Y, Ma H, Tai PWL, et al · · 2021 · cited 899× · PMID 33558455 · DOI 10.1038/s41392-021-00487-6
Oncolytic viruses for cancer immunotherapy.
Hemminki O, Dos Santos JM, Hemminki A. · · 2020 · cited 246× · PMID 32600470 · DOI 10.1186/s13045-020-00922-1
Viral vector-based gene therapies in the clinic.
Zhao Z, Anselmo AC, Mitragotri S. · · 2022 · cited 171× · PMID 35079633 · DOI 10.1002/btm2.10258
Recent advances of oncolytic virus in cancer therapy.
Mondal M, Guo J, He P, Zhou D. · · 2020 · cited 154× · PMID 32078405 · DOI 10.1080/21645515.2020.1723363
Inflammation and cancer: paradoxical roles in tumorigenesis and implications in immunotherapies.
Liu X, Yin L, Shen S, Hou Y. · · 2023 · cited 75× · PMID 37013041 · DOI 10.1016/j.gendis.2021.09.006
Concepts in Oncolytic Adenovirus Therapy.
Mantwill K, Klein FG, Wang D, Hindupur SV, et al · · 2021 · cited 75× · PMID 34638863 · DOI 10.3390/ijms221910522
Immunology of Adenoviral Vectors in Cancer Therapy.
Shaw AR, Suzuki M. · · 2019 · cited 62× · PMID 31890734 · DOI 10.1016/j.omtm.2019.11.001
Trial Watch: Oncolytic viro-immunotherapy of hematologic and solid tumors.
Pol JG, Lévesque S, Workenhe ST, Gujar S, et al · · 2018 · cited 61× · PMID 30524901 · DOI 10.1080/2162402x.2018.1503032

Verify or expand the search:

Other trials of VCN-01

Trials testing the same drug.

NCT05673811 — Study of Nab-Paclitaxel and Gemcitabine and Plus/Minus VCN-01 in Patients With Metastatic Pancreatic Cancer · Phase 2 · completed
NCT03799744 — Safety,Tolerability,and Efficacy of VCN-01 With Durvalumab in R/M Head and Neck Squamous Cell Carcinoma · Phase 1 · unknown

Other recruiting trials for Retinoblastoma, Recurrent

Currently open trials in the same condition.

NCT06725173 — Detailed Phenotypic and Genotype Study to Correlate RB1 Mutations Relating to Primary Ocular Tumors and Secondary Extra- · recruiting
NCT06972602 — High-dose Topotecan for Retinoblastoma With Recurrent or Refractory Vitreous Seed · EARLY_PHASE1 · recruiting

Other Fundació Sant Joan de Déu trials

Trials by the same sponsor.

NCT07508917 — Effects of 5-Methyltetrahydrofolic Acid Supplementation on Maternal Health and One-Carbon Metabolism During Lactation · Phase 1, PHASE2 · not yet recruiting
NCT06556251 — Effectiveness of a Digital Platform in Engagement and Prognosis of Patients in an Early Intervention Pychosis Programme · NA · recruiting
NCT06309121 — Effects of the Postbiotic Blend ABB C3 on Adiposity and Glucose Metabolism in Children and Adolescents · NA · active not recruiting
NCT07091344 — Cognitive and Metacognitive Evaluation in VR-Based Avatar Therapy for Psychosis · NA · recruiting
NCT06340555 — Intervention to Prevent Mental Health Disorders of Women and Their Partners Who Experienced Pregnancy Loss · NA · unknown

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03284268 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Fundació Sant Joan de Déu
Last refreshed: 27 August 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03284268.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing